Study protocol: Fecal Microbiota Transplant combined with Atezolizumab/Bevacizumab in Patients with Hepatocellular Carcinoma who failed to achieve or maintain objective response to Atezolizumab/Bevacizumab – the FAB-HCC pilot study

Authors

Adrian Frick (ORCID: https://orcid.org/0000-0003-1471-316X)
Katharina Lampichler (ORCID: https://orcid.org/0000-0002-9719-4694)
Christoph Gasché (ORCID: https://orcid.org/0000-0002-3752-6685)
Katharina Pomej (ORCID: https://orcid.org/0000-0002-2807-3565)
Dietmar Tamandl (ORCID: https://orcid.org/0000-0003-1996-0688)
Katharina Regnat
Bernhard Scheiner (ORCID: https://orcid.org/0000-0002-4904-5133)
Anton Klotz (ORCID: https://orcid.org/0009-0005-5469-6482)
Matthias Pinter (ORCID: https://orcid.org/0000-0002-7260-532X)
Alexander Kreuter (ORCID: https://orcid.org/0000-0003-2275-499X)
Michael A Trauner (ORCID: https://orcid.org/0000-0002-1275-6425)
Lorenz Balcar (ORCID: https://orcid.org/0000-0002-6708-3061)
Larissa Pajancic
Kerstin Zinober (ORCID: https://orcid.org/0009-0004-0451-1593)